Pasar al contenido principal

EFECTO DE LAS QUIMIOTERAPIAS EN TEJIDOS SANOS

PID2021-126568OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACIO INSTITUT DE RECERCA BIOMEDICA (BARCELONA)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Origins of second malignancies in children and mutational footprint of chemotherapy in normal tissues

  • Sánchez-Guixé, Mònica
  • Muiños, Ferran
  • Pinheiro Santin, Morena
  • González-Huici, Víctor
  • Rodríguez-Hernández, Carlos
  • Avgustinova, Alexandra
  • Lavarino, Cinzia
  • González-Pérez, Abel
  • Mora, Jaume
  • López Bigas, Núria
Pediatric cancers are rare diseases, and children without known germline predisposing conditions who develop a second malignancy during developmental ages are extremely rare. We present four such clinical cases and, through whole-genome and error-correcting ultra-deep duplex sequencing of tumor and normal samples, we explored the origin of the second malignancy in four children, uncovering different routes of development. The exposure to cytotoxic therapies was linked to the emergence of a secondary acute myeloid leukemia. A common somatic mutation acquired early during embryonic development was the driver of two solid malignancies in another child. In two cases, the two tumors developed from completely independent clones diverging during embryogenesis. Importantly, we demonstrate that platinum-based therapies contributed at least one order of magnitude more mutations per day of exposure than aging to normal tissues in these children., N. Lopez-Bigas acknowledges funding from the European Research Council (consolidator grant 682398). M. Sanchez-Guixe was supported by a postdoctoral contract with the Centro de Investigación Biomédica en Red de Cáncer (CIBERONC). This project was supported by the PID2021-126568OB-I00 (CHEMOHEALTH) project, funded by the Spanish Ministry of Science (MCIN), AEI 10.13039/501100011033/. It has also been supported by the project “Discovering the molecular signatures of cancer PROMotion to INform prevENTion” (PROMI­NENT) funded by Cancer Research UK (CGCATF-2021/100008), NCI (1OT2CA278668-01) and the Spanish Cancer Association, AECC. IRB Barcelona is a recipient of a Severo Ochoa Centre of Excellence Award from the Spanish Ministry of Economy and Competitiveness (MINECO; Government of Spain) and an Excellence Institutional grant by the Asociacion Española contra el Cancer, and is supported by CERCA (Generalitat de Catalunya). We are grateful to the Band of Parents at Hospital Sant Joan de Déu Barcelona for supporting the overall research activities of the developmental tumor laboratory, PCCB, and for having generously contributed with their samples. This study would have been impossible to reach without this contribution.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Strand-resolved mutagenicity of DNA damage and repair

  • Anderson, Craig J.
  • López Bigas, Núria
  • Taylor, Martin S.
DNA base damage is a major source of oncogenic mutations1. Such damage can produce strand-phased mutation patterns and multiallelic variation through the process of lesion segregation2. Here we exploited these properties to reveal how strand-asymmetric processes, such as replication and transcription, shape DNA damage and repair. Despite distinct mechanisms of leading and lagging strand replication3,4, we observe identical fidelity and damage tolerance for both strands. For small alkylation adducts of DNA, our results support a model in which the same translesion polymerase is recruited on-the-fly to both replication strands, starkly contrasting the strand asymmetric tolerance of bulky UV-induced adducts5. The accumulation of multiple distinct mutations at the site of persistent lesions provides the means to quantify the relative efficiency of repair processes genome wide and at single-base resolution. At multiple scales, we show DNA damage-induced mutations are largely shaped by the influence of DNA accessibility on repair efficiency, rather than gradients of DNA damage. Finally, we reveal specific genomic conditions that can actively drive oncogenic mutagenesis by corrupting the fidelity of nucleotide excision repair. These results provide insight into how strand-asymmetric mechanisms underlie the formation, tolerance and repair of DNA damage, thereby shaping cancer genome evolution., This work was supported by the MRC Human Genetics Unit core funding programme grants (MC_UU_00007/11, MC_UU_00007/16 and MC_UU_00035/2), MRC Toxicology Unit core funding (RG94521), Cancer Research UK Cambridge Institute funding (20412 and 22398) and European Molecular Biology Laboratory core funding. Support was also provided from specific research grants: PID2021-126568OB-I00 (CHEMOHEALTH) project, funded by the Spanish Ministry of Science (MCIN, AEI/10.13039/501100011033/); the Wellcome Trust (WT202878/B/16/Z); the European Research Council (615584 and 788937); Helmholtz NCT (DKFZ abteiling B270); the US NIH (R01GM083337); and the MRC equipment award (MC_PC_MR/X013677/1). Edinburgh Genomics is partly supported through core grants from the NERC (R8/H10/56), the MRC (MR/K001744/1) and the BBSRC (BB/J004243/1). J.C. was supported by a Wellcome Trust PhD Training Fellowship for Clinicians (WT223088/Z/21/Z) as part of the Edinburgh Clinical Academic Track (ECAT) programme. M.D.N. is a cross-disciplinary post-doctoral fellow supported by funding from the CRUK Brain Tumour Centre of Excellence Award (C157/A27589). O.P. was funded by a BIST PhD fellowship supported by the Secretariat for Universities and Research of the Ministry of Business and Knowledge of the Government of Catalonia and the Barcelona Institute of Science and Technology. V.S. was supported by an EMBL Interdisciplinary Postdoc (EIPOD) fellowship under Marie Skłodowska Curie actions COFUND (664726). P.-C.W. is supported by the ERC Starting Grant (BrainBreaks 949990) and a Helmholtz Young Investigator grant. S.J.A. received a Wellcome Trust PhD Training Fellowship for Clinicians (WT106563/Z/14/Z), an National Institute for Health and Care Research (NIHR) Clinical Lectureship and a CRUK Clinician Scientist Fellowship (RCCCSF-May23/100001).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Oncodrive3D: fast and accurate detection of structural clusters of somatic mutations under positive selection

  • Pellegrini, Stefano
  • Dove-Estrella, Olivia
  • Muiños, Ferran
  • López Bigas, Núria
  • González-Pérez, Abel
Identifying the genes capable of driving tumorigenesis in different tissues is one of the central goals of cancer genomics. Computational methods that exploit different signals of positive selection in the pattern of mutations observed in genes across tumors have been developed to this end. One such signal of positive selection is clustering of mutations in areas of the three-dimensional (3D) structure of the protein above the expectation under neutrality. Methods that exploit this signal have been hindered by the paucity of proteins with experimentally solved 3D structures covering their entire sequence. Here, we present Oncodrive3D, a computational method that, by exploiting AlphaFold 2 structural models, extends the identification of proteins with significant mutational 3D clusters to the entire human proteome. Oncodrive3D shows sensitivity and specificity on par with state-of-the-art cancer driver gene identification methods exploiting mutational clustering and clearly outperforms them in computational efficiency. We demonstrate, through several examples, how significant mutational 3D clusters identified by Oncodrive3D in different known or potential cancer driver genes can reveal details about the mechanism of tumorigenesis in different cancer types and in clonal hematopoiesis., This project has received funding from the European Union's Horizon Europe program HORIZON-HLTH-2021-CARE-05-02 for the project CGI-Clinics under grant agreement No. 101057509, and has also been supported by the PID2021-126568OB-I00 (CHEMOHEALTH) project, funded by the Spanish Ministry of Science (MCIN), AEI/10.13039/501100011033/. SP acknowledges the support of scholarship PRE2021-096986, funded by the Spanish Ministry of Science (MCIN)/AEI/10.13039/501100011033 and FSE. Funding to pay the Open Access publication charges for this article was provided by HORIZON-HLTH-2021-CARE-05-02 project funded by Horizon Europe.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Oncodrive3D: fast and accurate detection of structural clusters of somatic mutations under positive selection

  • Pellegrini, Stefano
  • Dove-Estrella, Olivia
  • Muiños, Ferran
  • López Bigas, Núria
  • González-Pérez, Abel
Identifying the genes capable of driving tumorigenesis in different tissues is one of the central goals of cancer genomics. Computational methods that exploit different signals of positive selection in the pattern of mutations observed in genes across tumors have been developed to this end. One such signal of positive selection is clustering of mutations in areas of the three-dimensional (3D) structure of the protein above the expectation under neutrality. Methods that exploit this signal have been hindered by the paucity of proteins with experimentally solved 3D structures covering their entire sequence. Here, we present Oncodrive3D, a computational method that, by exploiting AlphaFold 2 structural models, extends the identification of proteins with significant mutational 3D clusters to the entire human proteome. Oncodrive3D shows sensitivity and specificity on par with state-of-the-art cancer driver gene identification methods exploiting mutational clustering and clearly outperforms them in computational efficiency. We demonstrate, through several examples, how significant mutational 3D clusters identified by Oncodrive3D in different known or potential cancer driver genes can reveal details about the mechanism of tumorigenesis in different cancer types and in clonal hematopoiesis., This project has received funding from the European Union's Horizon Europe program HORIZON-HLTH-2021-CARE-05-02 for the project CGI-Clinics under grant agreement No. 101057509, and has also been supported by the PID2021-126568OB-I00 (CHEMOHEALTH) project, funded by the Spanish Ministry of Science (MCIN), AEI/10.13039/501100011033/. SP acknowledges the support of scholarship PRE2021-096986, funded by the Spanish Ministry of Science (MCIN)/AEI/10.13039/501100011033 and FSE. Funding to pay the Open Access publication charges for this article was provided by HORIZON-HLTH-2021-CARE-05-02 project funded by Horizon Europe.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Strand-resolved mutagenicity of DNA damage and repair

  • Anderson, Craig J.
  • López Bigas, Núria
  • Taylor, Martin S.
DNA base damage is a major source of oncogenic mutations1. Such damage can produce strand-phased mutation patterns and multiallelic variation through the process of lesion segregation2. Here we exploited these properties to reveal how strand-asymmetric processes, such as replication and transcription, shape DNA damage and repair. Despite distinct mechanisms of leading and lagging strand replication3,4, we observe identical fidelity and damage tolerance for both strands. For small alkylation adducts of DNA, our results support a model in which the same translesion polymerase is recruited on-the-fly to both replication strands, starkly contrasting the strand asymmetric tolerance of bulky UV-induced adducts5. The accumulation of multiple distinct mutations at the site of persistent lesions provides the means to quantify the relative efficiency of repair processes genome wide and at single-base resolution. At multiple scales, we show DNA damage-induced mutations are largely shaped by the influence of DNA accessibility on repair efficiency, rather than gradients of DNA damage. Finally, we reveal specific genomic conditions that can actively drive oncogenic mutagenesis by corrupting the fidelity of nucleotide excision repair. These results provide insight into how strand-asymmetric mechanisms underlie the formation, tolerance and repair of DNA damage, thereby shaping cancer genome evolution., This work was supported by the MRC Human Genetics Unit core funding programme grants (MC_UU_00007/11, MC_UU_00007/16 and MC_UU_00035/2), MRC Toxicology Unit core funding (RG94521), Cancer Research UK Cambridge Institute funding (20412 and 22398) and European Molecular Biology Laboratory core funding. Support was also provided from specific research grants: PID2021-126568OB-I00 (CHEMOHEALTH) project, funded by the Spanish Ministry of Science (MCIN, AEI/10.13039/501100011033/); the Wellcome Trust (WT202878/B/16/Z); the European Research Council (615584 and 788937); Helmholtz NCT (DKFZ abteiling B270); the US NIH (R01GM083337); and the MRC equipment award (MC_PC_MR/X013677/1). Edinburgh Genomics is partly supported through core grants from the NERC (R8/H10/56), the MRC (MR/K001744/1) and the BBSRC (BB/J004243/1). J.C. was supported by a Wellcome Trust PhD Training Fellowship for Clinicians (WT223088/Z/21/Z) as part of the Edinburgh Clinical Academic Track (ECAT) programme. M.D.N. is a cross-disciplinary post-doctoral fellow supported by funding from the CRUK Brain Tumour Centre of Excellence Award (C157/A27589). O.P. was funded by a BIST PhD fellowship supported by the Secretariat for Universities and Research of the Ministry of Business and Knowledge of the Government of Catalonia and the Barcelona Institute of Science and Technology. V.S. was supported by an EMBL Interdisciplinary Postdoc (EIPOD) fellowship under Marie Skłodowska Curie actions COFUND (664726). P.-C.W. is supported by the ERC Starting Grant (BrainBreaks 949990) and a Helmholtz Young Investigator grant. S.J.A. received a Wellcome Trust PhD Training Fellowship for Clinicians (WT106563/Z/14/Z), an National Institute for Health and Care Research (NIHR) Clinical Lectureship and a CRUK Clinician Scientist Fellowship (RCCCSF-May23/100001).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Origins of second malignancies in children and mutational footprint of chemotherapy in normal tissues

  • Sánchez-Guixé, Mònica
  • Muiños, Ferran
  • Pinheiro Santin, Morena
  • González-Huici, Víctor
  • Rodríguez-Hernández, Carlos
  • Avgustinova, Alexandra
  • Lavarino, Cinzia
  • González-Pérez, Abel
  • Mora, Jaume
  • López Bigas, Núria
Pediatric cancers are rare diseases, and children without known germline predisposing conditions who develop a second malignancy during developmental ages are extremely rare. We present four such clinical cases and, through whole-genome and error-correcting ultra-deep duplex sequencing of tumor and normal samples, we explored the origin of the second malignancy in four children, uncovering different routes of development. The exposure to cytotoxic therapies was linked to the emergence of a secondary acute myeloid leukemia. A common somatic mutation acquired early during embryonic development was the driver of two solid malignancies in another child. In two cases, the two tumors developed from completely independent clones diverging during embryogenesis. Importantly, we demonstrate that platinum-based therapies contributed at least one order of magnitude more mutations per day of exposure than aging to normal tissues in these children., N. Lopez-Bigas acknowledges funding from the European Research Council (consolidator grant 682398). M. Sanchez-Guixe was supported by a postdoctoral contract with the Centro de Investigación Biomédica en Red de Cáncer (CIBERONC). This project was supported by the PID2021-126568OB-I00 (CHEMOHEALTH) project, funded by the Spanish Ministry of Science (MCIN), AEI 10.13039/501100011033/. It has also been supported by the project “Discovering the molecular signatures of cancer PROMotion to INform prevENTion” (PROMI­NENT) funded by Cancer Research UK (CGCATF-2021/100008), NCI (1OT2CA278668-01) and the Spanish Cancer Association, AECC. IRB Barcelona is a recipient of a Severo Ochoa Centre of Excellence Award from the Spanish Ministry of Economy and Competitiveness (MINECO; Government of Spain) and an Excellence Institutional grant by the Asociacion Española contra el Cancer, and is supported by CERCA (Generalitat de Catalunya). We are grateful to the Band of Parents at Hospital Sant Joan de Déu Barcelona for supporting the overall research activities of the developmental tumor laboratory, PCCB, and for having generously contributed with their samples. This study would have been impossible to reach without this contribution.